Indications
Rezzayo is indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.
Composition
- Active substance
- rezafungin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rezzayo
- Active substance
- rezafungin
- ATC code
- J02AX08
- Therapeutic area
- Candidiasis, Candidiasis, Invasive
- Marketing authorisation holder
- Mundipharma GmbH
- Status
- Authorised
- EU authorisation